| # | Drug | Count |
|---|---|---|
| 0 | AZATHIOPRINE | 108 |
| 1 | RITUXIMAB | 100 |
| 2 | PREDNISONE | 98 |
| 3 | ROMIPLOSTIM | 89 |
| 4 | DANAZOL | 86 |
| 5 | VITAMIN C | 74 |
| 6 | CYCLOSPORINE | 60 |
| 7 | RABEPRAZOLE | 44 |
| 8 | RABEPRAZOLE SODIUM | 44 |
| 9 | HUMAN RHO(D) IMMUNE GLOBULIN | 39 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | HUMAN RHO(D) IMMUNE GLOBULIN | 39 | 0.0380 |
| 1 | DANAZOL | 86 | 0.0303 |
| 2 | VACCINIA IMMUNE GLOBULIN INTRAVENOUS (HUMAN) | 2 | 0.0227 |
| 3 | FERRIC SULFATE | 1 | 0.0125 |
| 4 | LIFILEUCEL | 2 | 0.0070 |
| 5 | PENICILLIN G | 15 | 0.0064 |
| 6 | ROMIPLOSTIM | 89 | 0.0059 |
| 7 | IMMUNE GLOBULIN INTRAVENOUS (HUMAN) | 35 | 0.0054 |
| 8 | ARTEMETHER AND LUMEFANTRINE | 1 | 0.0051 |
| 9 | DEFEROXAMINE MESYLATE | 7 | 0.0032 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 135 |
| 1 | Purine Antimetabolite [EPC] | 108 |
| 2 | CD20-directed Cytolytic Antibody [EPC] | 103 |
| 3 | Vitamin C [EPC] | 90 |
| 4 | Thrombopoietin Receptor Agonist [EPC] | 89 |
| 5 | Androgen [EPC] | 87 |
| 6 | Human Immunoglobulin G [EPC] | 62 |
| 7 | Calcineurin Inhibitor Immunosuppressant [EPC] | 60 |
| 8 | Nonsteroidal Anti-inflammatory Drug [EPC] | 50 |
| 9 | Platelet Aggregation Inhibitor [EPC] | 28 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Thrombopoietin Receptor Agonist [EPC] | 89 | 0.0059 |
| 1 | Androgen [EPC] | 87 | 0.0032 |
| 2 | Human Immunoglobulin G [EPC] | 62 | 0.0029 |
| 3 | Methylating Agent [EPC] | 2 | 0.0019 |
| 4 | Lymphocyte Growth Factor [EPC] | 2 | 0.0016 |
| 5 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 11 | 0.0013 |
| 6 | Purine Antimetabolite [EPC] | 108 | 0.0011 |
| 7 | Erythroid Maturation Agent [EPC] | 2 | 0.0008 |
| 8 | B Lymphocyte Stimulator-specific Inhibitor [EPC] | 20 | 0.0006 |
| 9 | CD52-directed Cytolytic Antibody [EPC] | 9 | 0.0005 |